Jules Bordet Institute registers Phase 2 scalp cooling trial for ADC-related hair lossNov 16Trial updateGilead Sciencessacituzumab govitecan
Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
FDA approved Trodelvy for HR-positive, HER2-negative breast cancerNov 10Regulatory decisionGilead Sciencessacituzumab govitecan
Gilead posts ARTISTRY-2 results; registers GS-1179 herpes trial and ARTISTRY-3 HIV studyNov 5Weekly roundup, 4 itemsbictegravirbictegravir/lenacapavirUpdated
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
BioNTech, BMS report Phase 2 pumitamig data in NSCLC after immunotherapy progressionOct 26Clinical readoutBioNTech SEBristol Myers SquibbUpdated
JAVELIN Bladder Medley results posted; Merck files separate MK-2010 trial across six tumor typesSep 1Weekly roundup, 2 itemsavelumabbelzutifan
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2Aug 5Quarterly updateRoyalty Pharma plc
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences